Current Gene Therapy

Ignacio Anegon
Director INSERM UMR 1064-Center for Research in Transplantation and Immunology
CHU de Nantes. 30, boulevard


Translate in Chinese

Integrase-Deficient Lentivirus: Opportunities and Challenges for Human Gene Therapy

Author(s): Kuan-Can Liu, Bao-Shun Lin, An-Ding Gao, Hong-Yu Ma, Meng Zhao, Rui Zhang, Hui-Hui Yan, Xun-Fei Yi, Si-Jie Lin, Jian-Wen Que, Xiao-Peng Lan.


Lentiviruses are powerful tools for gene delivery and have been widely used for the dissection of gene functions in both replicating and quiescent cells. Recently, lentiviruses have also been used for delivering target sequences in gene therapy. Although the lentiviral system provides sustained exogenous gene expression, serious concerns have been raised due to its unfavorable insertion-mediated mutagenesis effect, thereby resulting in the silencing or activation of some unexpected genes. Thus, an array of modifications of the original vectors may reduce risks. Here, we briefly review the structure of the integrase protein, which is an essential protein for viral insertion and integration; the mechanisms of integrase-mediated integration; and the effects of the modifications of integrase. Moreover, we discuss the advantages resulting from integrase modifications and their future applications. Taken together, the generation of integrase-deficient lentivirus (IDLV) not only provides us with an opportunity to reduce the risk of virus-mediated insertions, which would improve the safety of gene therapy, but also favors gene correction and vaccine development.

Keywords: Gene delivery, gene therapy, genome manipulation, integrase-deficient lentivirus, non-integrating lentiviral vectors.

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

Year: 2014
Page: [352 - 364]
Pages: 13
DOI: 10.2174/1566523214666140825124311
Price: $58